ReviewNature reviews. Neurology2016
Advanced tests for early and accurate diagnosis of Creutzfeldt-Jakob disease.
Review in Nature reviews. Neurology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 125 citations in OpenAlex.
- Suspected encephalitis in adults.Practical neurology · 2026Review
- Study on the final diagnosis of nervous system diseases with psychiatric symptoms as manifestation onset.BMC psychiatry · 2025Article
- Serial amplification of tau filaments using Alzheimer's brain homogenates and C322A or C322S recombinant tau.FEBS letters · 2025Article
- Applications of Digital Enzyme-Linked Immunosorbent Assays in Ophthalmology.Cell biochemistry and biophysics · 2025Review
- Biological Fluid Biomarkers in Human Prion Diseases with a Note on Biosafety.Sub-cellular biochemistry · 2025Review
- Diagnosis of Prion Diseases.Sub-cellular biochemistry · 2025Review
- Review
- Euphoric Presentation in Creutzfeldt-Jakob Disease and Its Diagnostic Implications: A Case Report.Cureus · 2024Article
- Plasmonic Fluorescence Sensors in Diagnosis of Infectious Diseases.Biosensors · 2024Review
- PRNP expression predicts imaging findings in sporadic Creutzfeldt-Jakob disease.Annals of clinical and translational neurology · 2023Article
- Seed amplification assay of nasal swab extracts for accurate and non-invasive molecular diagnosis of neurodegenerative diseases.Translational neurodegeneration · 2023Review
- Longitudinal detection of prion shedding in nasal secretions of CWD-infected white-tailed deer.The Journal of general virology · 2023Article
- Article
- Probing the origin of prion protein misfolding via reconstruction of ancestral proteins.Protein science : a publication of the Protein Society · 2022Article
- Fluid Biomarkers in Alzheimer's Disease and Other Neurodegenerative Disorders: Toward Integrative Diagnostic Frameworks and Tailored Treatments.Diagnostics (Basel, Switzerland) · 2022Review
- Comparison of cerebrospinal fluid tau, ptau(181), synuclein, and 14-3-3 for the detection of Creutzfeldt-Jakob disease in clinical practice.Journal of neural transmission (Vienna, Austria : 1996) · 2022Article
- The Future of Seed Amplification Assays and Clinical Trials.Frontiers in aging neuroscience · 2022Review
- Premortem diagnosis of pathologically confirmed sporadic Creutzfeldt-Jakob disease.Clinical case reports · 2021Article
- Protein Aggregation Landscape in Neurodegenerative Diseases: Clinical Relevance and Future Applications.International journal of molecular sciences · 2021Review
- Creutzfeldt-Jakob disease as a cause of dementia.BMJ case reports · 2021Article
Corrections and comments
- Erratum issued
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
Abstract
Early and accurate diagnosis of Creutzfeldt-Jakob disease (CJD) is a necessary to distinguish this untreatable disease from treatable rapidly progressive dementias, and to prevent iatrogenic transmission. Currently, definitive diagnosis of CJD requires detection of the abnormally folded, CJD-specific form of protease-resistant prion protein (PrP(CJD)) in brain tissue obtained postmortem or via biopsy; therefore, diagnosis of sporadic CJD in clinical practice is often challenging. Supporting investigations, including MRI, EEG and conventional analyses of cerebrospinal fluid (CSF) biomarkers, are helpful in the diagnostic work-up, but do not allow definitive diagnosis. Recently, novel ultrasensitive seeding assays, based on the amplified detection of PrP(CJD), have improved the diagnostic process; for example, real-time quaking-induced conversion (RT-QuIC) is a sensitive method to detect prion-seeding activity in brain homogenate from humans with any subtype of sporadic CJD. RT-QuIC can also be used for in vivo diagnosis of CJD: its diagnostic sensitivity in detecting PrP(CJD) in CSF samples is 96%, and its specificity is 100%. Recently, we provided evidence that RT-QuIC of olfactory mucosa brushings is a 97% sensitive and 100% specific for sporadic CJD. These assays provide a basis for definitive antemortem diagnosis of prion diseases and, in doing so, improve prospects for reducing the risk of prion transmission. Moreover, they can be used to evaluate outcome measures in therapeutic trials for these as yet untreatable infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.